Here are the staff publications for May 2024.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 5th June 2024.

1. Abdel-Wahab M, Coleman CN, Eriksen JG, Lee P, Kraus R, Harsdorf E, Lee B, Dicker A, Hahn E, Agarwal JP, Prasanna PGS, MacManus M, Keall P, Mayr NA, Jereczek-Fossa BA, Giammarile F, Kim IA, Aggarwal A, Lewison G, Lu JJ, Guedes de Castro D, Kong FS, Afifi H, Sharp H, Vanderpuye V, Olasinde T, Atrash F, Goethals L, Corn BW. Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities. Lancet Oncol 2024;25:e270-e80.
2. Acera Mateos P, A JS, Ravindran A, Srivastava A, Woodward K, Mahmud S, Kanchi M, Guarnacci M, Xu J, Z WSY, Zhou Y, Sneddon A, Hamilton W, Gao J, L MS, Hayashi R, Wickramasinghe V, Zarnack K, Preiss T, Burgio G, Dehorter N, N ES, Eyras E. Prediction of m6A and m5C at single-molecule resolution reveals a transcriptome-wide co-occurrence of RNA modifications. Nat Commun 2024;15:3899.
3. Alexander M, Jachno K, Phillips K-A, Seymour JF, Slavin MA, Cheung A, Shen V, Maarouf D, Wolfe R, Lingaratnam S. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice 2023;30:642-60.
4. Amir LH, Crawford SB, Cullinane M, Grzeskowiak LE. General practitioners' management of mastitis in breastfeeding women: a mixed method study in Australia. BMC Prim Care 2024;25:161.
5. Anderson RF, Shinde SS, Andrau L, Leung B, Skene C, White JM, Lobachevsky PN, Martin RF. Chemical Repair of Radical Damage to the GC Base Pair by DNA-Bound Bisbenzimidazoles. The Journal of Physical Chemistry B 2024;128:4367-76.
6. Ayati N, McIntosh L, Buteau J, Alipour R, Pudis M, Daw N, Jackson P, Hofman MS. Comparison of quantitative whole body PET parameters on [(68)Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer. Cancer Imaging 2024;24:57.
7. Bagaria SP, Swallow C, Suraweera H, Raut CP, Fairweather M, Cananzi F, Quagliuolo V, Grignani G, Hompes D, Ford SJ, Nessim C, Apte S, Skoczylas J, Rutkowski P, Bonvalot S, Tzanis D, Gabriel E, Pennacchioli E, Albertsmeier M, Canter RJ, Pollock R, Grignol V, Cardona K, Gamboa AC, Novak M, Stoeckle E, Almquist M, Ahuja N, Klemen N, Van Houdt W, Gyorki D, Gangi A, Rastrelli M, van der Hage J, Schrage Y, Valeri S, Conti L, Spiegel MR, Li Z, Fiore M, Gronchi A. Correction: Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology 2022;29:4388-9.
8. Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C, Hood BL, Conrads KA, Teng PN, Oliver J, Gist G, Mitchell D, Litzi TJ, Tarney CM, Crothers BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C, Meerzaman D, Bodelon C, Wentzensen N, Lee JSH, Huntsman DG, Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell DDL, Conrads TP, Maxwell GL. Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. NPJ Precis Oncol 2024;8:97.
9. Bland KA, France-Ratcliffe M, Krishnasamy M, Nandi A, Parr EB, Martin P, Cormie P, van Loon LJC, Zopf EM. "It gave me a sense of achievement and a sense of purpose"-a qualitative study of patient experiences of a virtually supervised exercise program for adults with advanced cancer and cachexia. Support Care Cancer 2024;32:325.
10. Buteau JP, Moon D, Fahey MT, Roberts MJ, Thompson J, Murphy DG, Papa N, Mitchell C, De Abreu Lourenco R, Dhillon HM, Kasivisvanathan V, Francis RJ, Stricker P, Agrawal S, O'Brien J, McVey A, Sharma G, Levy S, Ayati N, Nguyen A, Lee SF, Pattison DA, Sivaratnam D, Frydenberg M, Du Y, Titus J, Lee ST, Ischia J, Jack G, Hofman MS, Emmett L. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [(68)Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol 2024;7:544-52.
11. Cao X, Huber S, Ahari AJ, Traube FR, Seifert M, Oakes CC, Secheyko P, Vilov S, Scheller IF, Wagner N, Yépez VA, Blombery P, Haferlach T, Heinig M, Wachutka L, Hutter S, Gagneur J. Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes. Genome Med 2024;16:70.
12. Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. J Natl Cancer Inst 2024;116:717-27.
13. Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, Yap KM, Saw NYL, Li J, Chen AXY, Chan CW, Derrick EB, Todd KL, Tong J, Dunbar PA, Li J, Hoang TX, de Menezes MN, Petley EV, Kim JS, Nguyen D, Leung PSK, So J, Deguit C, Zhu J, House IG, Kats LM, Scott AM, Solomon BJ, Harrison SJ, Oliaro J, Parish IA, Quinn KM, Neeson PJ, Slaney CY, Lai J, Beavis PA, Darcy PK. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 2024;629:201-10.
14. Chan S, Morgan B, Yong MK, Margetts M, Farchione AJ, Lucas EC, Godsell J, Giang NA, Slade CA, von Borstel A, Bryant VL, Howson LJ. Cytomegalovirus drives Vδ1(+) γδ T cell expansion and clonality in common variable immunodeficiency. Nat Commun 2024;15:4286.
15. Choo N, Keerthikumar S, Ramm S, Ashikari D, Teng L, Niranjan B, Hedwards S, Porter LH, Goode DL, Simpson KJ, Taylor RA, Risbridger GP, Lawrence MG. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer. J Pathol 2024;263:242-56.
16. Chung H, Hyatt A, Webber K, Kosmider S, Krishnasamy M. Value in care: The contribution of supportive care to value-based lung cancer services-A qualitative semistructured interview study. Health Expect 2024;27:e14089.
17. Claudiani S, Chee L, Fernando F, Brown L, Achandira UM, Khan A, Rothwell K, Hayden C, Koutsavlis I, Hannah G, Innes A, Apperley JF, Milojkovic D. Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations. Am J Hematol 2024;99:1172-4.
18. Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips KA, Radbruch L, Thompson MK, Andre F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Inbah Rajah D, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Vargas Enciso V, Vaz-Luis I, Villarreal-Garza C, Lancet Breast Cancer C. The Lancet Breast Cancer Commission. Lancet 2024;403:1895-950.
19. Conyers R, Halman A, Moore C, Stenta T, Felmingham B, Collier L, Khatri D, Spelman T, Williams E, Dyas R, Kotecha RS, Jessop S, Mateos MK, Swen J, Elliott DA. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation. BMJ Open 2024;14:e085115.
20. Cooper L, Xu H, Polmear J, Kealy L, Szeto C, Pang ES, Gupta M, Kirn A, Taylor JJ, Jackson KJL, Broomfield BJ, Nguyen A, Gago da Graça C, La Gruta N, Utzschneider DT, Groom JR, Martelotto L, Parish IA, O'Keeffe M, Scharer CD, Gras S, Good-Jacobson KL. Type I interferons induce an epigenetically distinct memory B cell subset in chronic viral infection. Immunity 2024;57:1037-55.e6.
21. Curtis AR, Kiss N, Livingstone KM, Daly RM, Ugalde A. Exploring dietitians' practice and perspectives on the role of dietary patterns during cancer treatment: A qualitative study. PLoS One 2024;19:e0302107.
22. da Silva AA, Granger CL, Abo S, Sheehan J, Barson E, Beach L, Pound G, Ali Abdelhamid Y, Fetterplace K, Fini NA, Merolli M, Sloan E, Parry SM. "How Do I Test the Waters? How Do I Go Forward?": Codesigning a Supportive Pathway after Critical Illness. Ann Am Thorac Soc 2024;21:916-27.
23. Davis JE, Ludford-Menting M, Koldej R, Ritchie DS. Modified cell trace violet proliferation assay preserves lymphocyte viability and allows spectral flow cytometry analysis. Cytometry A 2024;105:394-403.
24. Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell 2024;42:850-68 e9.
25. Dufton PH, Gerdtz MF, Jarden R, Krishnasamy M. Factors that influence presentation to an emergency department during systemic anti-cancer therapy: An exploratory qualitative study. Eur J Oncol Nurs 2024;70:102607.
26. Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID, Investigators EN-pT, the A, New Zealand U, Prostate Cancer Trials G. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2024;25:563-71.
27. Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, Grigoriadis K, Pich O, Karasaki T, Hobson PS, Levi D, Veeriah S, Puttick C, Nye EL, Green M, Dijkstra KK, Shimato M, Akarca AU, Marafioti T, Salgado R, Hackshaw A, Jamal-Hanjani M, van Maldegem F, McGranahan N, Glass B, Pulaski H, Walk E, Reading JL, Quezada SA, Hiley CT, Downward J, Sahai E, Swanton C, Angelova M. Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer. Cancer Discov 2024;14:1018-47.
28. Fehlberg Z, Stark Z, Best S. Reanalysis of genomic data, how do we do it now and what if we automate it? A qualitative study. Eur J Hum Genet 2024;32:521-8.
29. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschabitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 2024;30:1505.
30. Gately L, Mesia C, Sepulveda JM, Del Barco S, Pineda E, Girones R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Penas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). J Neurooncol 2024;168:299-306.
31. Geukens T, Maetens M, Hooper JE, Oesterreich S, Lee AV, Miller L, Atkinson JM, Rosenzweig M, Puhalla S, Thorne H, Devereux L, Bowtell D, Loi S, Bacon ER, Ihle K, Song M, Rodriguez-Rodriguez L, Welm AL, Gauchay L, Murali R, Chanda P, Karacay A, Naceur-Lombardelli C, Bridger H, Swanton C, Jamal-Hanjani M, Kollath L, True L, Morrissey C, Chambers M, Chinnaiyan AM, Wilson A, Mehra R, Reichert Z, Carey LA, Perou CM, Kelly E, Maeda D, Goto A, Kulka J, Szekely B, Szasz AM, Tokes AM, Van Den Bogaert W, Floris G, Desmedt C. Research autopsy programmes in oncology: shared experience from 14 centres across the world. J Pathol 2024;263:150-65.
32. Gould C, McBean M, Thompson E, Lickiss J, Tiong IS, Westerman D, Blombery P. Observations from a national sample exchange program for molecular haematology testing. Pathology 2024;56:540-7.
33. Griffiths EA. Predictors of anastomotic leak and conduit necrosis after oesophagectomy: Results from the oesophago-gastric anastomosis audit (OGAA). Eur J Surg Oncol 2024;50:107983.
34. Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, Haskali MB, Sparks RB, Vlasyuk O, Galetic I. First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [(68)Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. J Nucl Med 2024;65:740-3.
35. Holze H, Talarmain L, Fennell KA, Lam EY, Dawson MA, Vassiliadis D. Analysis of synthetic cellular barcodes in the genome and transcriptome with BARtab and bartools. Cell Rep Methods 2024;4:100763.
36. Huang S, Chen DC, Mirabelli AG, Donato R, Pham T, Duong C, Lawrentschuk N. 'Case of the Month' from Epworth Healthcare, Epworth, Australia: Fournier's gangrene following routine surgery. BJU Int 2024;133:667-70.
37. Ishimura M, Eguchi K, Sonoda M, Tanaka T, Shiraishi A, Sakai Y, Yasumi T, Miyamoto T, Voskoboinik I, Hashimoto K, Matsumoto S, Ozono S, Moritake H, Takada H, Ohga S. Early hematopoietic cell transplantation for familial hemophagocytic lymphohistiocytosis in a regional treatment network in Japan. Int J Hematol 2024;119:592-602.
38. Jain N, Ryan AL, Haeusler GM, McMullan BJ, Moore AS, Bartlett AW, Blyth CC, Kotecha RS, Yeoh DK, Clark JE. Invasive fungal disease in children with solid tumors: An Australian multicenter 10-year review. Pediatr Blood Cancer 2024;71:e31031.
39. Jitmana K, Griffiths JI, Fereday S, DeFazio A, Bowtell D, Adler FR. Mathematical modeling of the evolution of resistance and aggressiveness of high-grade serous ovarian cancer from patient CA-125 time series. PLoS Comput Biol 2024;20:e1012073.
40. Kearney CJ, Vervoort SJ, Ramsbottom KM, Freeman AJ, Michie J, Peake J, Casanova J-L, Picard C, Tangye SG, Ma CS, Johnstone RW, Randall KL, Oliaro J. DOCK8 Drives Src-Dependent NK Cell Effector Function. The Journal of Immunology 2017;199:2118-27.
41. Lai-Kwon J, Thorner E, Rutherford C, Crossnohere N, Brundage M. Integrating Patient-Reported Outcomes Into the Care of People With Advanced Cancer-A Practical Guide. Am Soc Clin Oncol Educ Book 2024;44:e438512.
42. Laidsaar-Powell R, Giunta S, Butow P, Turner S, Costa D, Saunders C, Koczwara B, Kay J, Jefford M, Schofield P, Boyle F, Yates P, White K, Sundaresan P, Varadarajan S, Juraskova I. An online intervention to improve oncology health professional self-efficacy in communicating with carers: Hybrid effectiveness-implementation evaluation of the eTRIO program. Patient Educ Couns 2024;124:108251.
43. Lau DK, Collin JP, Mariadason JM. Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer. Biomedicines 2024;12.
44. Lau LS, Allingham C, Anazodo A, Sullivan M, Peate M, Hunter S, Stern C, Ryan AL, Super L, Orme LM, McCarthy M, Gook D, Lewin J, Marino J, Ryan J, Downie P, Manudhane R, Winstanley M, Pettit T, Lantsberg D, Irving H, Reid S, Heath JA, Kabalan-Baeza P, Wanaguru D, Moore L, Gillam L, Zacharin M, Assis M, Rozen G, Hunter T, Julania S, Sharwood E, Ameratunga D, Jayasinghe Y. The Australian New Zealand Consortium in Children, Adolescents, and Young Adults Oncofertility action plan. Pediatr Blood Cancer 2024;71:e31041.
45. Le K, Le KDR, Nguyen J, Hua J, Munday S. The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder. Pain Ther 2024;13:435-55.
46. Le KDR, Tay SBP, Choy KT, Verjans J, Sasanelli N, Kong JCH. Applications of natural language processing tools in the surgical journey. Front Surg 2024;11:1403540.
47. Lee TS, Li I, Peric B, Saw RPM, Duprat JP, Bertolli E, Spillane JB, van Leeuwen BL, Moncrieff M, Sommariva A, Allan CP, de Wilt JHW, Jones RP, Geh JLC, Howle JR, Spillane AJ. Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial. Ann Surg Oncol 2024;31:4061-70.
48. Leech M, Abdalqader A, Alexander S, Anderson N, Barbosa B, Callens D, Chapman V, Coffey M, Cox M, Curic I, Dean J, Denney E, Kearney M, Leung VWS, Mortsiefer M, Nirgianaki E, Povilaitis J, Strikou D, Thompson K, van den Bosch M, Velec M, Woodford K, Buijs M. The Radiation Therapist profession through the lens of new technology: A practice development paper based on the ESTRO Radiation Therapist Workshops. Tech Innov Patient Support Radiat Oncol 2024;30:100243.
49. Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB, Investigators B-CMS. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. J Clin Oncol 2024;42:1766-75.
50. Lim LL, Williams K, Francis J, Wroth M, Breen J. Feasibility of a Nurse-Led Intervention to Reduce Urine Dipstick Testing in Long-Term Residential Aged Care Homes. J Am Med Dir Assoc 2024;25:104947.
51. Lim SL, Wellard C, Moore E, Harrison SJ, Hang Q, Ho J, Rajagopal R, Spencer A. Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry. Intern Med J 2024;54:773-8.
52. Loh Z, Ashby M, Van Veldhuizen E, Li W, Chee A, Aung W, Lavrukhina Y, Mason G, Pelly T, Nedumannil R, Kosciejew S, Mokoonlall M, Lim J, Calov G, Butler L, Hillebrand P, Beekman A, Rathnasekara GK, Raj S, Zhang C, Yao Y, Iland H, Grigg A. Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia. Br J Haematol 2024;204:1732-9.
53. Lynch F, Best S, Gaff C, Downie L, Archibald AD, Gyngell C, Goranitis I, Peters R, Savulescu J, Lunke S, Stark Z, Vears DF. Australian public perspectives on genomic newborn screening: which conditions should be included? Hum Genomics 2024;18:45.
54. MacPhail A, Dendle C, Slavin M, McQuilten Z. Hospital-acquired bloodstream infections in patients with cancer: current knowledge and future directions. J Hosp Infect 2024;148:39-50.
55. MacPhail A, Dendle C, Slavin M, Weinkove R, Bailey M, Pilcher D, McQuilten Z. Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study. Crit Care 2024;28:148.
56. Nelson A, Ho PJ, Haysom H, Waters N, Wellard C, Chee M, Teo J, Greenway A, Mason K, Kidson-Gerber G, Kaplan Z, Carter T, Cole-Sinclair MF, Barbaro P, Wood EM, Haemoglobinopathy Registry i. Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry. Intern Med J 2024;54:764-72.
57. Ng AP, Adams R, Tiong IS, Seymour L, Talaulikar D, Palfreyman E, Enjeti A, Tate C. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations. Pathology 2024;56:459-67.
58. Ng J, Cai L, Girard L, Prall OWJ, Rajan N, Khoo C, Batrouney A, Byrne DJ, Boyd DK, Kersbergen AJ, Christie M, Minna JD, Burr ML, Sutherland KD. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clin Cancer Res 2024;30:1846-58.
59. Ninkovic S, Purton LE, Harrison SJ, Quach H. Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients. Haematologica 2024;109:1487-500.
60. Noor A, Roselt PD, McGowan ER, Poniger S, Wheatcroft MP, Donnelly PS. Automated synthesis of [(89)Zr]ZrCl(4), [(89)Zr]ZrDFOSquaramide-bisPh(PSMA) and [(89)Zr]ZrDFOSquaramide-TATE. EJNMMI Radiopharm Chem 2024;9:39.
61. O'Sullivan NJ, Temperley HC, Larkin J, McCormick JJ, Rausa E, McCormick P, Heriot A, Mehigan BJ, Warrier S, Kelly ME. Robotic transanal minimally invasive surgery (R-TAMIS): current evidence in the treatment of early rectal neoplasia. Int J Colorectal Dis 2024;39:71.
62. Obinata D, Takayama K, Lawrence MG, Funakoshi D, Hara M, Niranjan B, Teng L, Taylor RA, Risbridger GP, Takahashi S, Inoue S. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor. BMC Cancer 2024;24:554.
63. Oda H, Manthiram K, Chavan PP, Rieser E, Veli O, Kaya O, Rauch C, Nakabo S, Kuehn HS, Swart M, Wang Y, Celik NI, Molitor A, Ziaee V, Movahedi N, Shahrooei M, Parvaneh N, Alipour-Olyei N, Carapito R, Xu Q, Preite S, Beck DB, Chae JJ, Nehrebecky M, Ombrello AK, Hoffmann P, Romeo T, Deuitch NT, Matthiasardottir B, Mullikin J, Komarow H, Stoddard J, Niemela J, Dobbs K, Sweeney CL, Anderton H, Lawlor KE, Yoshitomi H, Yang D, Boehm M, Davis J, Mudd P, Randazzo D, Tsai WL, Gadina M, Kaplan MJ, Toguchida J, Mayer CT, Rosenzweig SD, Notarangelo LD, Iwai K, Silke J, Schwartzberg PL, Boisson B, Casanova JL, Bahram S, Rao AP, Peltzer N, Walczak H, Lalaoui N, Aksentijevich I, Kastner DL. Biallelic human SHARPIN loss of function induces autoinflammation and immunodeficiency. Nat Immunol 2024;25:764-77.
64. Ovruchesky E, Pan E, Guer M, Elliott A, Siva S, Ravi P, McGregor B, Bagrodia A, Derweesh I, Barata P, Heath EI, Antonarakis ES, Darabi S, Hoon DSB, Mortazavi A, Choueiri TK, Nabhan C, Wei S, McKay RR. Characterization of FOLH1 Expression in Renal Cell Carcinoma. Cancers (Basel) 2024;16.
65. Pasricha SR, Rogers L, Branca F, Garcia-Casal MN. Measuring haemoglobin concentration to define anaemia: WHO guidelines. Lancet 2024;403:1963-6.
66. Peffault de Latour R, Griffin M, Kelly RJ, Szer J, de Castro C, Horneff R, Tan L, Yeh M, Panse J. Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Adv 2024;8:2718-25.
67. Ranasinghe C, Kariyawasam K, Liyanage J, Walpita Y, Rajasinghe U, Abayadeera A, Chandrasinghe P, Gunasekara M, Kumarage S, De Silva M, Ranathunga K, Deen K, Ismail H. Translation, cross-cultural adaptation, and validation of the Duke Activity Status Index (DASI) to Sinhala language. Perioper Med (Lond) 2024;13:38.
68. Ruschoff J, Kumar G, Badve S, Jasani B, Krause E, Rioux-Leclercq N, Rojo F, Martini M, Cheng L, Tretiakova M, Mitchell C, Anders RA, Robert ME, Fahy D, Pyle M, Le Q, Yu L, Glass B, Baxi V, Babadjanova Z, Pratt J, Brutus S, Karasarides M, Hartmann A. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. Virchows Arch 2024;484:597-608.
69. Sinclair M, Song R, Peate M, Saunders C, Lippey J, Umstad MP, Mason K, Ives A, Stafford L. Experiences of cohabiting partners of women diagnosed with cancer during pregnancy: a qualitative study. Support Care Cancer 2024;32:384.
70. Siva S, Moon D, Pryor D. Stereotactic ablative radiotherapy for primary kidney cancer - Authors' reply. Lancet Oncol 2024;25:e230.
71. Steinfort DP, Kothari G, Wallace N, Hardcastle N, Rangamuwa K, Dieleman EMT, Lee P, Li P, Simpson JA, Yo S, Bashirdazeh F, Nguyen P, Jennings BR, Fielding D, Crombag L, Irving LB, Yasufuku K, Annema JT, Ost DE, Siva S. Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial. Lancet Respir Med 2024;12:467-75.
72. Stewart NP, Quinlan C, Best S, Mynard JP. Noninvasive pediatric blood pressure assessment: exploring the clinicians' perspective. Blood Press Monit 2024;29:127-35.
73. Szabo RA, Molloy E, Allen KJ, Francis J, Story D. Leaders' experiences of embedding a simulation-based education programme in a teaching hospital: an interview study informed by normalisation process theory. Adv Simul (Lond) 2024;9:21.
74. Taieb J, Basile D, Seligmann J, Argiles G, André T, Gallois C, Goldberg RM, Yothers G, Sobrero A, Meyerhardt JA, Souglakos J, Labianca R, Iveson T, Church DN, Arnold D, Tie J, Gill S, Laurent-Puig P, Yoshino T, Lonardi S, Shi Q. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts. Eur J Cancer 2024;206:114118.
75. Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv 2024;8:2300-9.
76. Tran HT, Kratina T, Coutansais A, Michalek D, Hogan BM, Lawlor KE, Vince JE, Silke J, Lalaoui N. RIPK3 cleavage is dispensable for necroptosis inhibition but restricts NLRP3 inflammasome activation. Cell Death Differ 2024;31:662-71.
77. Voruganti Maddali IS, Cunningham C, McLeod L, Bahig H, Chaudhuri N, K LMC, Evison M, Faivre-Finn C, Franks K, Harden S, Videtic G, Lee P, Senan S, Siva S, Palma DA, Phillips I, Kruser J, Kruser T, Peedell C, Melody Qu X, Robinson C, Wright A, Harrow S, Louie AV. Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study. Lung Cancer 2024;192:107822.
78. Vu J, Koh C, Solomon M, Brown K, Karunaratne S, Cole R, Smith P, Raichurkar P, Denehy L, Riedel B, Steffens D. Patients' and carers' views on research priorities in prehabilitation for cancer surgery. Support Care Cancer 2024;32:378.
79. Wakkerman FC, Wu J, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens L, Haverkort MAD, de Jong MA, Mens JWM, Wortman BG, Nout RA, Léon-Castillo A, Powell ME, Mileshkin LR, Katsaros D, Alfieri J, Leary A, Singh N, de Boer SM, Nijman HW, Smit V, Bosse T, Koelzer VH, Creutzberg CL, Horeweg N. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials. Lancet Oncol 2024;25:779-89.
80. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol 2024;85:511-6.
81. Weickhardt A, Foroudi F, Lawrentschuk N, Xie J, Sidhom M, Pal A, Grimison P, Zhang A, Ng S, Tang C, Hovey E, Chen C, Hruby G, Guminski A, McJannett M, Conduit C, Tran B, Davis ID, Hayne D. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). Eur Urol Oncol 2024;7:469-77.
82. Wheeler G, Grassberger C, Samers J, Dwyer M, Wiltshire K, Daly P, Alvarez B, Campbell BA, Kerr AJ, Kron T, Duane FK, Zacharin M, Downie P, Kyriakou E, Ronckers CM, Constine LS, Hiniker SM. Central Endocrine Complications Among Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys 2024;119:457-66.
83. Wickramasinghe SU, Ramanathan V, Sarasanandarajah S, De Zoyza M, Paranamana R. Occupational dose measurement in interventional cardiology practice. Radiat Prot Dosimetry 2024;200:629-39.
84. Yuan Z, van Delft MF, Li MX, Sumardy F, Smith BJ, Huang DCS, Lessene G, Khakam Y, Jin R, He S, Smith NA, Birkinshaw RW, Czabotar PE, Dewson G. Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis. PLoS Biol 2024;22:e3002617.
85. Zhao Y, Haworth A, Reynolds HM, Williams SG, Finnegan R, Rowshanfarzad P, Ebert MA. Towards optimal heterogeneous prostate radiotherapy dose prescriptions based on patient-specific or population-based biological features. Med Phys 2024;51:3766-81.